AstraZeneca to upgrade US listing but retain London base
29th Sep 2025 09:17
(Alliance News) - AstraZeneca PLC on Monday announced plans to upgrade its US listing but said it will keep its London trading and UK headquarters. Read More
(Alliance News) - AstraZeneca PLC on Monday announced plans to upgrade its US listing but said it will keep its London trading and UK headquarters. Read More
(Alliance News) - GSK PLC Chief Executive Emma Walmsley will step down from the start of next year, the pharmaceutical firm announced Monday, with chief commercial officer Luke Miels named as its next boss. Read More
(Alliance News) - Stock prices in London opened higher on Monday amid gains for GSK and AstraZeneca, while the gold price continued to climb. Read More
(Alliance News) - AstraZeneca plans changes to its US listing and to retain its position in London, GSK promotes its chief commercial officer to lead the company while Merchants Trust raises its dividend. Read More
(Alliance News) - The FTSE 100 recorded strong gains on Friday as US data pointed to resilient consumer spending and relatively subdued inflation, keeping hoped for rate cuts across the pond on track. Read More
(Alliance News) - Stocks in London fell on Thursday and the pound dipped - while strong US data boosted the dollar - as talk of a political challenge to Keir Starmer saw UK bond yields climb. Read More
(Alliance News) - London stocks were mixed at midday on Wednesday, following a Wall Street slump on Tuesday as investors digested US President Donald Trump's turnaround on the conflict in Ukraine. Read More
(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Wednesday said the US Food & Drug Administration has granted priority review for Enhertu in combination with pertuzumab as a first-line treatment for adults with HER2-positive metastatic breast cancer. Read More
(Alliance News) - Blue chips in London faded into the close on Tuesday, ending little changed, as worries over economic growth and inflation overshadowed strong results from Kingfisher. Read More
(Alliance News) - AstraZeneca PLC on Monday said two drugs have been recommended for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More
(Alliance News) - London's FTSE is set to open lower on Monday, following a rate hold by China's central bank and the risk of heightened geopolitical tensions following the recognition of a Palestinian state by the UK, Australia, Canada and Portugal over the weekend. Read More
(Alliance News) - AstraZeneca PLC on Friday said new long-term clinical trial data reinforce Ultomiris as a transformative treatment for neuromyelitis optica spectrum disorder, or NMOSD, a rare autoimmune disease that can cause blindness and paralysis. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - AstraZeneca PLC on Wednesday reported mixed updates from its late-stage pipeline, with a lupus treatment hitting its main goal in a phase III trial, while a chronic obstructive pulmonary disease candidate fell short. Read More
(Alliance News) - Britain and the US have struck a tech deal that could bring billions of pounds of investment to the UK as President Donald Trump arrived for his second state visit. Read More
(Alliance News) - Stock prices in London closed mostly lower on Monday, as markets mainly price in an interest rate cut from the US Federal Reserve, and a hold from the Bank of England, this week. Read More
(Alliance News) - Stock prices in Europe were largely on the up on Monday, though the FTSE 100 underwhelmed, while the dollar was on the decline ahead of an expected US Federal Reserve rate cut. Read More
(Alliance News) - Daiichi Sankyo Co Ltd on Thursday said the European Medicines Agency has validated the application for Enhertu to treat patients with a range of tumours. Read More
(Alliance News) - European stocks opened largely in the green on Thursday, as investors gear up for a US inflation reading and a European Central Bank decision. Read More
(Alliance News) – AstraZeneca PLC said on Sunday that its Tagrisso lung cancer treatment plus chemotherapy delivered the longest survival benefits recorded in phase three trials. Read More